Current guidelines for the management of small cell lung cancer

Research output: Contribution to journalArticle

50 Citations (Scopus)

Abstract

Small cell lung cancer (SCLC) accounts for 20% to 25% of cases of bronchogenic carcinoma and results in pronounced morbidity and mortality in the United States. More than 90% of cases of SCLC are caused by cigarette smoking. Common pulmonary manifestations are dyspnea, persistent cough, hemoptysis, and postobstructive pneumonia. At the time of diagnosis, patients usually have extensive disease. To date, therapeutic approaches have made only modest advances in outcome. Combined modality approaches, such as radiotherapy administered concomitantly with the initiation of chemotherapy, induction chemotherapy followed by radiotherapy administered during the subsequent courses of chemotherapy, sequential chemotherapy and radiotherapy, and courses of radiotherapy split between cycles of chemotherapy, are important for improving survival in patients with SCLC.

Original languageEnglish (US)
Pages (from-to)809-816
Number of pages8
JournalMayo Clinic Proceedings
Volume74
Issue number8
StatePublished - 1999

Fingerprint

Small Cell Lung Carcinoma
Radiotherapy
Guidelines
Drug Therapy
Induction Chemotherapy
Hemoptysis
Bronchogenic Carcinoma
Cough
Dyspnea
Pneumonia
Smoking
Morbidity
Lung
Survival
Mortality
Therapeutics

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Current guidelines for the management of small cell lung cancer. / Adjei, Alex; Marks, Randolph Stuart; Bonner, James A.

In: Mayo Clinic Proceedings, Vol. 74, No. 8, 1999, p. 809-816.

Research output: Contribution to journalArticle

@article{4dc5c98bb726475ca1ae58119ebaea6e,
title = "Current guidelines for the management of small cell lung cancer",
abstract = "Small cell lung cancer (SCLC) accounts for 20{\%} to 25{\%} of cases of bronchogenic carcinoma and results in pronounced morbidity and mortality in the United States. More than 90{\%} of cases of SCLC are caused by cigarette smoking. Common pulmonary manifestations are dyspnea, persistent cough, hemoptysis, and postobstructive pneumonia. At the time of diagnosis, patients usually have extensive disease. To date, therapeutic approaches have made only modest advances in outcome. Combined modality approaches, such as radiotherapy administered concomitantly with the initiation of chemotherapy, induction chemotherapy followed by radiotherapy administered during the subsequent courses of chemotherapy, sequential chemotherapy and radiotherapy, and courses of radiotherapy split between cycles of chemotherapy, are important for improving survival in patients with SCLC.",
author = "Alex Adjei and Marks, {Randolph Stuart} and Bonner, {James A.}",
year = "1999",
language = "English (US)",
volume = "74",
pages = "809--816",
journal = "Mayo Clinic Proceedings",
issn = "0025-6196",
publisher = "Elsevier Science",
number = "8",

}

TY - JOUR

T1 - Current guidelines for the management of small cell lung cancer

AU - Adjei, Alex

AU - Marks, Randolph Stuart

AU - Bonner, James A.

PY - 1999

Y1 - 1999

N2 - Small cell lung cancer (SCLC) accounts for 20% to 25% of cases of bronchogenic carcinoma and results in pronounced morbidity and mortality in the United States. More than 90% of cases of SCLC are caused by cigarette smoking. Common pulmonary manifestations are dyspnea, persistent cough, hemoptysis, and postobstructive pneumonia. At the time of diagnosis, patients usually have extensive disease. To date, therapeutic approaches have made only modest advances in outcome. Combined modality approaches, such as radiotherapy administered concomitantly with the initiation of chemotherapy, induction chemotherapy followed by radiotherapy administered during the subsequent courses of chemotherapy, sequential chemotherapy and radiotherapy, and courses of radiotherapy split between cycles of chemotherapy, are important for improving survival in patients with SCLC.

AB - Small cell lung cancer (SCLC) accounts for 20% to 25% of cases of bronchogenic carcinoma and results in pronounced morbidity and mortality in the United States. More than 90% of cases of SCLC are caused by cigarette smoking. Common pulmonary manifestations are dyspnea, persistent cough, hemoptysis, and postobstructive pneumonia. At the time of diagnosis, patients usually have extensive disease. To date, therapeutic approaches have made only modest advances in outcome. Combined modality approaches, such as radiotherapy administered concomitantly with the initiation of chemotherapy, induction chemotherapy followed by radiotherapy administered during the subsequent courses of chemotherapy, sequential chemotherapy and radiotherapy, and courses of radiotherapy split between cycles of chemotherapy, are important for improving survival in patients with SCLC.

UR - http://www.scopus.com/inward/record.url?scp=0032805404&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032805404&partnerID=8YFLogxK

M3 - Article

VL - 74

SP - 809

EP - 816

JO - Mayo Clinic Proceedings

JF - Mayo Clinic Proceedings

SN - 0025-6196

IS - 8

ER -